CryoLife (CRY) Receiving Somewhat Positive News Coverage, Study Finds

News headlines about CryoLife (NYSE:CRY) have been trending somewhat positive on Sunday, according to Accern Sentiment. The research firm identifies negative and positive media coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. CryoLife earned a daily sentiment score of 0.17 on Accern’s scale. Accern also assigned media headlines about the medical equipment provider an impact score of 46.1213718299535 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.

Here are some of the media headlines that may have effected Accern’s rankings:

A number of research analysts have weighed in on the company. Zacks Investment Research lowered CryoLife from a “buy” rating to a “sell” rating in a report on Wednesday, August 2nd. BidaskClub downgraded CryoLife from a “hold” rating to a “sell” rating in a research report on Tuesday, August 1st. Finally, Northland Securities reiterated a “buy” rating and set a $23.50 price target on shares of CryoLife in a research report on Friday, April 28th. Two analysts have rated the stock with a sell rating and three have assigned a buy rating to the company. The company currently has an average rating of “Hold” and a consensus price target of $22.00.

CryoLife (NYSE CRY) traded up 0.27% during trading on Friday, hitting $18.40. The stock had a trading volume of 75,296 shares. CryoLife has a 12 month low of $14.02 and a 12 month high of $20.30. The stock has a 50 day moving average price of $19.30 and a 200-day moving average price of $17.96. The stock has a market cap of $615.41 million, a price-to-earnings ratio of 55.76 and a beta of 0.97.

CryoLife (NYSE:CRY) last released its quarterly earnings data on Monday, July 24th. The medical equipment provider reported $0.12 EPS for the quarter, topping the consensus estimate of $0.10 by $0.02. The company had revenue of $47.80 million for the quarter, compared to the consensus estimate of $47.02 million. CryoLife had a return on equity of 7.41% and a net margin of 6.16%. CryoLife’s quarterly revenue was up 1.5% on a year-over-year basis. During the same period last year, the business posted $0.13 EPS. On average, equities analysts predict that CryoLife will post $0.43 EPS for the current year.

In other news, VP Amy Horton sold 9,577 shares of CryoLife stock in a transaction on Tuesday, June 27th. The stock was sold at an average price of $20.00, for a total value of $191,540.00. Following the transaction, the vice president now directly owns 112,282 shares in the company, valued at approximately $2,245,640. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 6.00% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This piece was originally published by BNB Daily and is owned by of BNB Daily. If you are viewing this piece on another website, it was stolen and republished in violation of United States and international trademark and copyright law. The legal version of this piece can be accessed at

About CryoLife

CryoLife, Inc (CryoLife) is a medical device manufacturer and processor, and is engaged in the distribution of medical devices and implantable human tissues used in cardiac surgical procedures. The Company operates through two segments: Medical Devices and Preservation Services. The Medical Devices segment includes medical devices, such as BioGlue Surgical Adhesive, BioFoam Surgical Matrix, On-X Life Technologies Holdings, Inc valves and surgical products, CardioGenesis cardiac laser therapy product line, PerClot and PhotoFix.

Insider Buying and Selling by Quarter for CryoLife (NYSE:CRY)

Receive News & Ratings for CryoLife Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CryoLife Inc. and related companies with's FREE daily email newsletter.

Latest News

Leave a Reply